These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Pettibone DJ; Totaro JA; Pflueger AB Eur J Pharmacol; 1984 Jul; 102(3-4):425-30. PubMed ID: 6489435 [TBL] [Abstract][Full Text] [Related]
4. Cerebral blood flow and cerebrovascular permeability in an inescapable shock (learned helplessness) animal model of depression. Hughes CW; Kent TA; Campbell J; Oke A; Croskell H; Preskorn SH Pharmacol Biochem Behav; 1984 Dec; 21(6):891-4. PubMed ID: 6441169 [TBL] [Abstract][Full Text] [Related]
5. Effects of tetrabenazine on methamphetamine-induced hyperactivity in mice are dependent on order and time-course of administration. Kuribara H Pharmacol Biochem Behav; 1997 Jan; 56(1):9-14. PubMed ID: 8981603 [TBL] [Abstract][Full Text] [Related]
6. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. Reches A; Burke RE; Kuhn CM; Hassan MN; Jackson VR; Fahn S J Pharmacol Exp Ther; 1983 Jun; 225(3):515-21. PubMed ID: 6864517 [TBL] [Abstract][Full Text] [Related]
7. Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. Pettibone DJ; Pflueger AB; Totaro JA Eur J Pharmacol; 1984 Jul; 102(3-4):431-6. PubMed ID: 6149131 [TBL] [Abstract][Full Text] [Related]
8. Animal model of depression. III. Mechanism of action of tetrabenazine. Tachiki KH; Takagi A; Tateishi T; Kido A; Nishiwaki K; Nakamura E; Nagayama H; Takahashi R Biol Psychiatry; 1978 Aug; 13(4):429-43. PubMed ID: 150867 [TBL] [Abstract][Full Text] [Related]
9. Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex. Kitanaka N; Kitanaka J; Hall FS; Kandori T; Murakami A; Muratani K; Nakano T; Uhl GR; Takemura M Pharmacol Biochem Behav; 2018 Sep; 172():9-16. PubMed ID: 30017858 [TBL] [Abstract][Full Text] [Related]
10. Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior. Yohn SE; Collins SL; Contreras-Mora HM; Errante EL; Rowland MA; Correa M; Salamone JD Neuropsychopharmacology; 2016 Feb; 41(3):686-94. PubMed ID: 26105139 [TBL] [Abstract][Full Text] [Related]
11. Serotonin metabolism of animal model of depression. Takahashi R; Tateishi T; Yoshida H; Nagayama H; Tachiki KH Adv Exp Med Biol; 1981; 133():603-25. PubMed ID: 6172020 [TBL] [Abstract][Full Text] [Related]
12. The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine. Podurgiel SJ; Yohn SE; Dortche K; Correa M; Salamone JD Behav Brain Res; 2016 Feb; 298(Pt B):188-91. PubMed ID: 26590367 [TBL] [Abstract][Full Text] [Related]
13. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs. Leysen JE; Eens A; Gommeren W; van Gompel P; Wynants J; Janssen PA J Pharmacol Exp Ther; 1988 Jan; 244(1):310-21. PubMed ID: 3336007 [TBL] [Abstract][Full Text] [Related]
14. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor. Podurgiel SJ; Nunes EJ; Yohn SE; Barber J; Thompson A; Milligan M; Lee CA; López-Cruz L; Pardo M; Valverde O; Lendent C; Baqi Y; Müller CE; Correa M; Salamone JD Neuroscience; 2013 Oct; 250():507-19. PubMed ID: 23867769 [TBL] [Abstract][Full Text] [Related]
15. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Dhir A; Kulkarni SK Eur J Pharmacol; 2007 Jul; 568(1-3):177-85. PubMed ID: 17509558 [TBL] [Abstract][Full Text] [Related]
16. Antidepressants alter cerebrovascular permeability and metabolic rate in primates. Preskorn SH; Raichle ME; Hartman BK Science; 1982 Jul; 217(4556):250-2. PubMed ID: 7089562 [TBL] [Abstract][Full Text] [Related]
17. Effect of CO2 on a brain extracellular space marker and evidence of its neuronal modulation. Kent TA; Nagy G; Oke AF; Preskorn SH; Adams RN Brain Res; 1985 Sep; 342(1):141-4. PubMed ID: 3929997 [TBL] [Abstract][Full Text] [Related]
18. The depletion and recovery of noradrenaline in the brain and some sympathetically innervated mammalian tissues after tetrabenazine. Häggendal J J Pharm Pharmacol; 1968 May; 20(5):364-7. PubMed ID: 4385439 [No Abstract] [Full Text] [Related]
19. Effects of tricyclic antidepressants on tetrabenazine-induced depletion of brain monoamines in rats. 1. Norepinephrine. Yoshizaki T; Tonda K Jpn J Pharmacol; 1980 Oct; 30(5):721-9. PubMed ID: 7206378 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic profile of fezolamine fumarate: a nontricyclic antidepressant in animal models. Baizman ER; Ezrin AM; Ferrari RA; Luttinger D J Pharmacol Exp Ther; 1987 Oct; 243(1):40-54. PubMed ID: 3668867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]